Tzachi Slonim, ed., "Richard M. Billow's Selected Papers on Psychoanalysis and Group Process" (Routledge, 2021)
Listen now
On this episode, J.J. Mull speaks with Richard Billow and Tzachi Slonim about Richard M. Billow’s Selected Papers on Psychoanalysis and Group Process: Changing Our Minds (Routledge, 2021). This volume presents Billow’s unique contributions to the theory and technique of psychoanalytic group therapy, along with introductions and explications by Slonim, the volume’s editor. Weaving together various theoretical traditions and thinkers (Bion, Laplanche, the relational school, etc.), Billow extends and complicates what we ordinarily think of as constituting the “relational” in psychodynamic group work. In addition to these theoretical contributions, what remains most alive in the book is its fidelity to clinical experience. Throughout the book, vivid clinical vignettes give us a window into the dynamic, unfolding process of a clinician at work. J.J. Mull is a poet, training clinician, and fellow in the Program for Psychotherapy at Cambridge Health Alliance. Originally from the west coast, he currently lives and bikes in Somerville, MA. He can be reached at: [email protected] Learn more about your ad choices. Visit Support our show by becoming a premium member!
More Episodes
Today I talked to Michaela Chamberlain, author of Misogyny in Psychoanalysis (Phoenix Publishing House, 2022) Chamberlain’s book is a product of “cumulative trauma” whose original starting point was an interest in in menstruation where, in psychoanalytic literature filled with papers on...
Published 05/27/23
The monumental sense of dislocation we experience after losing a loved one can be life-altering. There is no script for grieving–each individual passes through their own phases of mourning. In Don't Be Sad When I'm Gone': A Memoir of Loss and Healing in Buenos Aires (Toplight Books, 2020),...
Published 05/26/23
In this episode, Bita Moghaddam discusses the emergence of ketamine as a combat anesthetic in the Vietnam war, its transformation into a recreation drug central to club culture, and its current transition into a treatment for depression.  Ketamine, approved in 2019 by the Food and Drug...
Published 05/12/23